Epigenetics in pain and analgesia: an imminent research field.

Epigenetic suppression of GAD65 expression mediates persistent pain. Nat Med (2011) 2.17

Epigenetic regulation of opioid-induced hyperalgesia, dependence, and tolerance in mice. J Pain (2013) 0.98

Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory. Neurobiol Learn Mem (2013) 0.98

Epigenetics and the transition from acute to chronic pain. Pain Med (2012) 0.93

p300 exerts an epigenetic role in chronic neuropathic pain through its acetyltransferase activity in rats following chronic constriction injury (CCI). Mol Pain (2012) 0.88

Epigenetics: a promising paradigm for better understanding and managing pain. J Pain (2013) 0.81

Epigenetics in the perioperative period. Br J Pharmacol (2015) 0.81

Epigenetic regulation of persistent pain. Transl Res (2014) 0.80

Psychological stress as a modulator of functional recovery following spinal cord injury. Front Neurol (2014) 0.79

Expression of acetylated histone 3 in the spinal cord and the effect of morphine on inflammatory pain in rats. Neural Regen Res (2012) 0.79

Temporal distribution of p300/CBP immunoreactivity in the adult rat spinal dorsal horn following chronic constriction injury (CCI). Cell Mol Neurobiol (2012) 0.78

Epigenetic regulation of spinal cord gene expression controls opioid-induced hyperalgesia. Mol Pain (2014) 0.78

Effects of methyl donor diets on incisional pain in mice. PLoS One (2013) 0.77

Extended-release hydrocodone - gift or curse? J Pain Res (2013) 0.76

The role for epigenetic modifications in pain and analgesia response. Nurs Res Pract (2013) 0.76

EZH2 regulates spinal neuroinflammation in rats with neuropathic pain. Neuroscience (2017) 0.75

Guest Editorial. Br J Pain (2013) 0.75

[Neuropathic pain : How to open the blackbox]. Schmerz (2015) 0.75

[Chronic pain care : Reality and entitlement]. Schmerz (2016) 0.75

GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med (2006) 3.38

Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int J Cancer (2012) 2.80

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst (2006) 2.51

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09

Pattern of neuropathic pain induced by topical capsaicin application in healthy subjects. Pain (2015) 2.07

Opioids for chronic non-cancer pain. BMJ (2013) 2.07

Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01

Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain (2009) 1.92

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 1.80

Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov (2009) 1.66

Reliable screening for a pain-protective haplotype in the GTP cyclohydrolase 1 gene (GCH1) through the use of 3 or fewer single nucleotide polymorphisms. Clin Chem (2007) 1.64

Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol (2003) 1.59

Chain length-specific properties of ceramides. Prog Lipid Res (2011) 1.57

No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci (2009) 1.54

Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51

Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics (2006) 1.50

COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther (2005) 1.46

Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet (2013) 1.46

Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther (2002) 1.46

Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. Blood (2006) 1.40

Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev (2004) 1.40

FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol (2007) 1.38

Ziconotide for treatment of severe chronic pain. Lancet (2010) 1.34

Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther (2003) 1.31

Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell (2007) 1.30

The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? FASEB J (2008) 1.29

Current evidence for a genetic modulation of the response to analgesics. Pain (2006) 1.27

The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics (2006) 1.27

Chronic opioid use is associated with increased DNA methylation correlating with increased clinical pain. Pain (2013) 1.26

Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain (2008) 1.26

Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci (2004) 1.24

Olfactory function in mild cognitive impairment and Alzheimer's disease: an investigation using psychophysical and electrophysiological techniques. Am J Psychiatry (2003) 1.21

Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol (2004) 1.21

G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res (2003) 1.20

Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci (2010) 1.19

Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer (2009) 1.17

Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol (2012) 1.17

Peripheral opioid analgesia in experimental human pain models. Brain (2003) 1.17

Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis (2009) 1.15

Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med (2005) 1.14

Quick discrimination of A(delta) and C fiber mediated pain based on three verbal descriptors. PLoS One (2010) 1.14

Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation (2008) 1.14

Principle components analysis of pain thresholds to thermal, electrical, and mechanical stimuli suggests a predominant common source of variance. Pain (2008) 1.14

GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J Am Coll Cardiol (2008) 1.13

Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J (2006) 1.12

Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens (2009) 1.11

Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One (2010) 1.11

Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J (2005) 1.10

cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I. J Neurosci (2008) 1.10

A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem (2008) 1.10

Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics (2009) 1.10

FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol (2007) 1.09

Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology (2002) 1.09

R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One (2010) 1.08

Phenotyping the function of TRPV1-expressing sensory neurons by targeted axonal silencing. J Neurosci (2013) 1.06

Effect sizes in experimental pain produced by gender, genetic variants and sensitization procedures. PLoS One (2011) 1.06

PAM mediates sustained inhibition of cAMP signaling by sphingosine-1-phosphate. EMBO J (2004) 1.06

A short olfactory test based on the identification of three odors. J Neurol (2010) 1.05

Clinical significance of results from olfactory testing. Laryngoscope (2006) 1.05

Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol (2002) 1.05

The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res (2008) 1.04

Sphingosine 1-phosphate modulates spinal nociceptive processing. J Biol Chem (2008) 1.04

Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain (2009) 1.03

5,6-EET is released upon neuronal activity and induces mechanical pain hypersensitivity via TRPA1 on central afferent terminals. J Neurosci (2012) 1.03

A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers. PLoS One (2012) 1.00

Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum Mol Genet (2012) 1.00

Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood (2010) 1.00

Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis (2003) 1.00

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics (2009) 0.99

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther (2006) 0.99

PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem Pharmacol (2007) 0.99

Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol (2008) 0.99

LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. Prostaglandins Other Lipid Mediat (2006) 0.98

Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol (2010) 0.98

Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes (2005) 0.98

Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett (2002) 0.98

Antioxidant activity of sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal (2013) 0.98

The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol (2008) 0.97

Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther (2003) 0.97

Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain. Clin Pharmacol Ther (2003) 0.97

Separating brain processing of pain from that of stimulus intensity. Hum Brain Mapp (2011) 0.97

Current evidence for a modulation of nociception by human genetic polymorphisms. Pain (2007) 0.97

Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem (2010) 0.97

Current evidence for a modulation of low back pain by human genetic variants. J Cell Mol Med (2009) 0.96

Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem (2002) 0.96

Is mPGES-1 a promising target for pain therapy? Trends Pharmacol Sci (2006) 0.95

Pharmacogenetics of new analgesics. Br J Pharmacol (2011) 0.95